Theory vs. Conclusion: An Ongoing Issue In Scientific Discussions
According to the CDC, "We are still learning about how the virus spreads and the severity of illness it causes," yet so much information about COVID-19 that we hear in the mainstream media (MSM) and political leaders is presented as "fact." Any alternative viewpoints are often dismissed, quieted or suppressed.
Early Treatment of COVID
Dr. Peter McCullough MD is an internist, cardiologist and epidemiologist, managing the cardiovascular complications of both the viral infection and injuries developing after the COVID-19 vaccine in Dallas, Texas.
Dr. McCullough published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,” in the American Journal of Medicine.
Mass Vaccinations During a Pandemic
Geerrt Vanden Bossche, Phd, DVM is an Independent Researcher who previously served as the Head of Vaccine Development for the German Centre for Infection Research, and the Program Manager for the Global Alliance for Vaccines and Immunisation (GAVI) — a collaboration between the World Health Organization, Bill & Melinda Gates Foundation, CDC, and UNICEF. Dr. Bossche also served as the Senior Program Officer of Global Health and Vaccine Discovery for the Bill & Melinda Gates Foundation.
Available COVID-19 Vaccines
According to an article on icandecide.org: Many Americans have been led to believe that a COVID-19 vaccine will prevent individuals from having a serious case of COVID-19 and will stop people from spreading it to others. However, the clinical trials for Pfizer, Moderna, AstraZeneca, and Johnson & Johnson’s products are not designed to determine either of these.
Both Pfizer and Moderna published data suggesting that COVID-19 vaccines might reduce the spread of virus, but the data requires closer scrutiny according to many mainstream media outlets, including Time Magazine.
The FDA initially only provided Emergency Use Authorization (EUA) of three separate COVID-19 vaccines in 2020, and then later gave approval to Pfizer’s COVID-19 vaccine Monday, August 23, 2021 under the title "COMIRNATY." Since the announcement, some health freedom advocates suggest that rebranding the Pfizer-BioNTech vaccine allows Moderna and Janssen—as well as the originally branded Pfizer COVID-19 vaccine—to remain under EUA and distribution since COMIRNATY is not readily available as of yet.*
You can find the latest information about authorization vs. approval at the following FDA web address: FDA.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
Regarding Pfizer's COMIRNATY COVID-19 Vaccine
“... it’s concerning that full approval is based on only six months’ worth of data — despite clinical trials designed for two years — and there’s no control group after Pfizer offered the product to placebo participants before the trials were completed.” - Kim Witczak, a drug safety advocate who serves as a consumer representative on the FDA’s Psychopharmacologic Drugs Advisory Committee
On December 18, 2020, the FDA issued the second emergency use authorization (EUA) for the Moderna COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years and older.
On February 27, 2021, the FDA issued the third emergency use authorization (EUA) for the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years and older.
*This information may be updated since publishing.
**Citing insufficient data, the World Health Organization’s latest guidance on Moderna’s COVID vaccine recommends most pregnant women, and anyone under age 18, not get the vaccine. Read more at Pregnant or Under 18? Don’t Get Moderna’s COVID Vaccine, WHO Says • Children's Health Defense
COVID-19 Vaccine Studies
Incomplete Pfizer-BioNTech studies and their completion dates
BLA approval letter (FDA.gov)
Deferred pediatric Study to evaluate the safety and effectiveness of COMIRNATY in children 12 years through 15 years of age.
Study Completion: May 31, 2023
Deferred pediatric Study to evaluate the safety and effectiveness of COMIRNATY in infants and children 6 months to <12 years of age.
Study Completion: November 30, 2023
Deferred pediatric Study to evaluate the safety and effectiveness of COMIRNATY in infants <6 months of age.
Study Completion: July 31, 2024
Study to describe the natural history of myocarditis and pericarditis following administration of COMIRNATY.
Study Completion: March 31, 2024
Study: Vaccinated carry 251 times the load of COVID-19 viruses in their nostrils compared to unvaccinated
Oxford University Clinical Research Group
The Lancet August 10, 2021
Study: Vaccinated may play a key role in helping SARS-CoV-2 variants
Scientific Reports July 30, 2021
More coming to this section soon.
Yale researchers identified several specific sex-linked immune system differences that can impact on male susceptibility to severe COVID-19, as well as to female heightened reactivity to COVID-19 vaccination. It appeared that women tended to mount a stronger T-cell response to infection in general. In contrast, men in the early stages of COVID-19 infection showed higher levels of cytokines, inflammatory proteins involved in the “first response” to invading pathogens.
Read the full article at the vaccinereaction.org